Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Ligusticolide I in the preparation of antidepressant drugs, migraine drugs and other serotonergic system-related disease drugs

A technology of liguscaridone and migraine, which is applied in the field of new medical application of lisanthemum lactone I, and can solve problems such as reduction and reduction of aggregation

Inactive Publication Date: 2012-02-08
SHANGHAI ZHANGJIANG ENG RES CENT OF MODERN PREPARATION TECH OF TRADITIONAL CHINESE MEDICINE +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still few reports on its pharmacological effects at present, and it is only found that it can reduce the deformable damage of ConA-induced erythrocytes and reduce its aggregation (Shi Zhen Guoyi Guoyao, 2003, 14 (12): 738-739.); Calcium influx in cardiomyocytes and human neurocytoma; reduce NO in the brainstem of animal models of ischemia-reperfusion, and inhibit the activity of NO synthase (Clin Exp Pharmacology Physion, 1999, 26: 845-846.)
There are no reports or patents on its activity in antidepressant and migraine treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Ligusticolide I in the preparation of antidepressant drugs, migraine drugs and other serotonergic system-related disease drugs
  • Application of Ligusticolide I in the preparation of antidepressant drugs, migraine drugs and other serotonergic system-related disease drugs
  • Application of Ligusticolide I in the preparation of antidepressant drugs, migraine drugs and other serotonergic system-related disease drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Embodiment 1 (alcohol extraction method chromatographic preparation of Ligustilide I)

[0015] Chuanxiong decoction pieces 1kg, after removing impurities, crushed into powder, 70% ethanol 10L reflux extraction twice, 2 hours each time, combined extracts, recovered solvent to obtain about 100g of extract A. The extract was separated by silica gel column chromatography (F100*1000mm). Chloroform-methanol was eluted at 50:1, the 4th-6th BV fraction was collected, and the recovered solvent was purified by a gel column (sephedex LH-20, F20*1500mm), eluted with methanol, and the samples were collected by pointing the plate to obtain purified Ligusticolactone I.

Embodiment 2

[0016] Embodiment 2 (the effect of Liguscaractone I on rat plasma and brain tissue monoamine transmitters)

[0017] 60 SD rats, half male and half female, body weight (250 ± 20) g, were randomly divided into 6 groups: blank control group, model group, positive drug group, ligustalactone I high, medium and low dose groups. Fasted for 12 h before the experiment, and had free access to water. Modeling method: In addition to the normal group, subcutaneous injection of absolute ethanol 4ml·kg -1 In addition, the other groups were subcutaneously injected with nitroglycerin 10mg / kg. Administration was given 30 minutes after modeling. The positive drug group was given 1.23mg·kg -1 The aqueous solution of ergotamine and caffeine tablets; the high, medium and low dose groups of Ligustilide I were given 72mg·kg by intragastric administration respectively. -1 、36mg·kg -1 , 18mg·kg -1 Ligusticolide I aqueous solution, and the other groups were intragastrically administered equal volu...

Embodiment 3

[0033] Embodiment 3 (the impact of Liguscaractone I on rat plasma and brain tissue NO)

[0034] Fifteen SD rats, male, weighing (250±20) g, were randomly divided into 3 groups: blank control group, model group, and administration group. Fasted for 12 h before the experiment, and had free access to water. Modeling method: In addition to the blank control group, subcutaneous injection of absolute ethanol 4ml kg -1 In addition, the model group and the model administration group were subcutaneously injected with nitroglycerin 10 mg kg -1 . Administration was given 30 minutes after modeling. The administration group was given 72mg·kg by intragastric administration -1 Ligusticolide I aqueous solution, and the other groups were intragastrically administered equal volumes of distilled water. 4 hours after administration, 6ml of blood was collected from the abdominal aorta, injected into a heparinized centrifuge tube, mixed evenly, 4000r·min -1 Centrifuge for 10 minutes to separa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new medical application of senkyunolide I. Inventor adopts animal model, has studied the effect of chuanxionglide I on rat plasma and brain tissue monoamine transmitter, the influence of chuanxionglide I on rat plasma and brain tissue NO and the effect of chuanxionglide I on rat plasma and brain tissue NO. The impact of mouse pain threshold, subsequent examples and pharmacological results thereof will confirm that Ligustin I has the ability to regulate monoamine transmitters, especially the content of 5-hydroxytryptamine (5-HT) in blood plasma and brain tissue, so Ligustilide I can be used to prepare medicines for preventing and treating depression, migraine, and other diseases related to serotonergic system.

Description

technical field [0001] The invention relates to the technical fields of traditional Chinese medicine chemistry and medicine, in particular to a new medical application of senkyunolide I extracted and prepared from Ligusticumchuanxiong Hort. Background technique [0002] Chuanxiong (Ligusticum chuanxiong Hort.) is a plant of the genus Ligusticum in the family Umbelliferae, and its medicinal part is the rhizome. Chuanxiong is a traditional Chinese medicine in my country. It has the effects of promoting blood circulation and promoting qi, dispelling wind and relieving pain. It was listed as a top grade in the Eastern Han Dynasty "Shen Nong's Materia Medica", and it is a commonly used traditional Chinese medicine for treating depression and migraine. [0003] Phthalides are a class of compounds present in Rhizoma Chuanxiong, which have been shown to be active in cardiovascular, blood and smooth muscle. Among them, butylphthalide, which has been studied more, has many activities...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/365A61P25/24A61P25/06A61P43/00
CPCA61K31/365A61P25/06A61P25/24A61P43/00
Inventor 冯怡徐德生梁爽
Owner SHANGHAI ZHANGJIANG ENG RES CENT OF MODERN PREPARATION TECH OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com